



Information on the compensation of corporate officers

(in application of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code)

The combined general meeting of MaaT Pharma (the “**Company**”) which was held on June 20, 2025 9.30 a.m. at the registered office of the Company located 70 avenue Tony Garnier – 69007 Lyon, approved the resolution relating to the compensation policy for corporate officers in respect of the 2025 financial year (*Say on Pay ex-ante*), as well as the resolution relating to the information mentioned in I. of article L. 22-10-9 of the French Commercial Code (*Code de commerce*) relating to the compensation paid and/or granted to corporate officers in respect of the financial year ending December 31, 2024 (so-called “global” *Say on Pay ex-post*).

Pursuant to the provisions of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code, this information is presented below, supplemented for information purposes by the results of the votes on the resolutions relating to the individual compensation paid and/or allocated to the Company's corporate officers in respect of the financial year ending December 31, 2024 (so-called “individual” *Say on Pay ex-post*).

| Resolution | Description | Results of the votes | Corresponding section in the 2024 Universal Registration Document (URD) |
|-----------------------|---|----------------------------|--|
| THIRTEENTH RESOLUTION | Approval of the information relating to the remuneration of corporate officers for the year 2024 mentioned in I of Article L. 22-10-9 of the French Commercial Code | Approved by 99,67 % | Universal Registration Document (Section 13 of the URD); Paragraph 13.2 (<i>Ratio</i>) |
| FOURTEENTH RESOLUTION | Approval of the elements of compensation paid during or allocated by way of the financial year 2024 to the Chairman of the Board of Directors | Approved by 99,66% | Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1 (<i>Corporate officers Compensation - Chairman of the Board of Directors</i>) |

| | | | |
|------------------------|--|---------------------|---|
| FIFTEENTH RESOLUTION | Approval of the elements of compensation paid during or allocated by way of the financial year 2024 to the Chief Executive Officer | Approved by 99,51 % | Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 <i>(Corporate officers Compensation - CEO)</i> |
| SIXTEENTH RESOLUTION | Approval of the remuneration policy applicable for 2025 to the Chairman of the Board of Directors | Approved by 99,66% | Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1 <i>(Corporate officers Compensation - Chairman of the Board of Directors)</i> |
| SEVENTEENTH RESOLUTION | Approval of the remuneration policy applicable for 2025 to the Chief Executive Officer | Approved by 99,51% | Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 <i>(Corporate officers Compensation - CEO)</i> |
| EIGHTEENTH RESOLUTION | Approval of the remuneration policy applicable for 2025 to directors | Approved by 99,66% | Universal Registration Document (Section 13 of the URD); Paragraph 13.1.2 <i>(Directors compensation)</i> |

* * *

About MaaT Pharma

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.

As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.



Contacts

MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com

Rx Communications Group – U.S. Investor Relations

Michael Miller
Managing Director
+1-917-633-6086
mmiller@rxir.com

MaaT Pharma – Media Relations

Pauline RICHAUD
Senior PR & Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com

Catalytic Agency – U.S. Media Relations

Heather Shea
Media relations for MaaT Pharma
+1 617-286-2013
heather.shea@catalyticagency.com